<DOC>
	<DOC>NCT02227849</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficacy of Canagliflozin (TA-7284) in combination with GLP-1 analogue in patients with type 2 Diabetes for 52 weeks.</brief_summary>
	<brief_title>Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With GLP-1 Analogue in Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>This is an open-label study to evaluate the long-term safety and efficacy of Canagliflozin (TA-7284) in Japanese patients with type 2 diabetes mellitus, who are receiving treatment with GLP-1 analogue on diet and exercise and have inadequate glycemic control. The patients will receive TA-7284 100mg orally for 52 weeks.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Canagliflozin</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<criteria>Patients who has been receiving a stable dose and regimen of GLP1 analogue over 12 weeks before administration of investigational dug Patients who are under dietary management and taking therapeutic exercise for diabetes over 12 weeks before administration of investigational drug Patients with HbA1c of ≥7.0% and &lt;10.5% Patients who were not administered diabetes therapeutic drugs prohibited for concomitant use within 12 weeks before administration of investigational drug Patients with type 1 diabetes mellitus, diabetes mellitus resulting from pancreatic disorder, or secondary diabetes mellitus (Cushing's syndrome, acromegaly, etc.) Patients with severe diabetic complications (proliferative diabetic retinopathy, stage 4 nephropathy, or serious diabetic neuropathy) Patients with hereditary glucosegalactose malabsorption or primary renal glucosuria Patients with systolic blood pressure of ≥160 mmHg or diastolic blood pressure of ≥100 mmHg Patients with serious renal or hepatic disease Patients with eGFR of &lt;45 mL/min/1.73 m2 Patients who are the excessive alcohol addicts Patients requiring insulin therapy Patients who are pregnant, lactating and probably pregnant patients and patients who can not agree to contraception</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>insulin resistance</keyword>
</DOC>